<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1609">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 08, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04627584</url>
  </required_header>
  <id_info>
    <org_study_id>MW33-2020-CP201</org_study_id>
    <nct_id>NCT04627584</nct_id>
  </id_info>
  <brief_title>A Phase 2 Clinical Trial of MW33 Injection in Patients With COVID-19</brief_title>
  <official_title>A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 2 Clinical Trial of MW33 Injection to Evaluate the Efficacy and Safety in Patients With Mild or Moderate COVID-19</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mabwell (Shanghai) Bioscience Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mabwell (Shanghai) Bioscience Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed as a multicenter, randomized, double-blind, placebo-controlled&#xD;
      clinical trial to evaluate the clinical efficacy and safety of MW33 injection in patients&#xD;
      with mild or moderate COVID-19, and to evaluate its pharmacokinetic profile and&#xD;
      immunogenicity.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 2021</start_date>
  <completion_date type="Anticipated">September 2021</completion_date>
  <primary_completion_date type="Anticipated">May 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>SARS-CoV-2 viral load</measure>
    <time_frame>7 Days</time_frame>
    <description>Change in time-weighted SARS-CoV-2 viral load in nasopharyngeal swabs from baseline to day 7</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Covid19</condition>
  <arm_group>
    <arm_group_label>MW33 injection-1200mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>MW33 injection-2400mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>MW33 injection</intervention_name>
    <description>a recombinant fully human antibody to coronavirus</description>
    <arm_group_label>MW33 injection-1200mg</arm_group_label>
    <arm_group_label>MW33 injection-2400mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>MW33 injection placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients diagnosed with mild or moderate COVID-19 (as per the Diagnosis and Treatment&#xD;
             Protocol for Novel Coronavirus Pneumonia (Trial, 8th edition), China, or Clinical&#xD;
             Management of COVID-19, WHO);&#xD;
&#xD;
          2. Has at least one COVID-19 symptom, e.g., fever, cough, shortness of breath, sore&#xD;
             throat, headache, muscle ache, and other respiratory or gastrointestinal symptoms, and&#xD;
             has the symptom for ≤ 7 days prior to randomization;&#xD;
&#xD;
          3. The SARS-CoV-2 nasopharyngeal nucleic acid is tested to be positive (RT-PCR), IgM&#xD;
             (-)/IgG (-) or IgM (+)/IgG (-) within 3 days before randomization;&#xD;
&#xD;
          4. Male or female subjects aged 18 to 80 years (including 18 and 80 years);&#xD;
&#xD;
          5. Subjects do not have a pregnancy plan, voluntarily take effective contraceptive&#xD;
             measures during the screening period and the next 6 months, and have no sperm and egg&#xD;
             donation plans, and voluntarily take non-pharmaceutical contraception measures during&#xD;
             the trial period;&#xD;
&#xD;
          6. Subjects voluntarily sign the informed consent form (ICF) based on sufficient&#xD;
             knowledge of the nature, purpose, and procedures of the study, and shall be willing to&#xD;
             comply with the study regulations.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. A subject who was diagnosed with severe or critical COVID-19 (as per the Diagnosis and&#xD;
             Treatment Protocol for Novel Coronavirus Pneumonia (Trial, 8th edition), China, or&#xD;
             Clinical Management of COVID-19, WHO);&#xD;
&#xD;
          2. Abnormal important organ function indicators, which meet the following conditions:&#xD;
&#xD;
             ① Liver function: serum aspartate aminotransferase (AST) and serum alanine&#xD;
             aminotransferase (ALT) &gt; 5.0 × upper limit of normal (ULN);&#xD;
&#xD;
             ② Renal function: patients treated with dialysis or eGFR&lt; 60 mL/min.&#xD;
&#xD;
             ③ Cardiac function: patients with results of 12-lead ECG suggesting conduction block&#xD;
             or acute myocardial infarction requiring urgent management;&#xD;
&#xD;
          3. Suspected or diagnosed with serious bacterial, fungal, viral, or other infection&#xD;
             (except SARS-CoV-2 infection). In the opinion of the investigator, the conditions will&#xD;
             prevent a subject from completing the study or impact interpretation of the study&#xD;
             results;&#xD;
&#xD;
          4. Currently suffering from serious systemic diseases or mental disorders, and ineligible&#xD;
             to participate in the study judged by the investigator;&#xD;
&#xD;
          5. A history of severe trauma, fracture, or surgery within 4 weeks prior to screening, or&#xD;
             possibility of requiring a major surgery during the study;&#xD;
&#xD;
          6. Participated in clinical trials of SARS-CoV-2 vaccine or SARS-CoV-2 monoclonal&#xD;
             antibody;&#xD;
&#xD;
          7. Received or being receiving the convalescent plasma from patients recovered from&#xD;
             COVID-19;&#xD;
&#xD;
          8. Prior or current use of antiviral drugs for treatment of COVID-19, including&#xD;
             Remdesivir, Tocilizumab, Interferon, Ribavirin, Abidol, Lopinavir, and Ritonavir, etc.&#xD;
&#xD;
          9. Currently enrolled into clinical studies with other drugs or devices; the time to&#xD;
             start of this study from the end of previous participation in other drug clinical&#xD;
             studies is less than 30 days, or within 5 half-lives, or within the biological effect&#xD;
             period of the drug (whichever is longer);&#xD;
&#xD;
         10. Those who are known to be allergic to any component of the investigational product; or&#xD;
             those who have a history of allergies and judged by the investigator to be ineligible&#xD;
             for enrollment;&#xD;
&#xD;
         11. Females who are pregnant or lactating;&#xD;
&#xD;
         12. Any conditions that are not suitable for enrollment judged by the investigator.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Bei ZHAO, Master</last_name>
    <phone>+86-18817773189</phone>
    <email>bei.zhao@mabwell.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Song LU, Master</last_name>
    <phone>15216868129</phone>
    <email>song.lu@mabwell.com</email>
  </overall_contact_backup>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>November 12, 2020</study_first_submitted>
  <study_first_submitted_qc>November 12, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 13, 2020</study_first_posted>
  <last_update_submitted>December 22, 2020</last_update_submitted>
  <last_update_submitted_qc>December 22, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 23, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

